ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2016 American Transplant Congress

    Non-Human Primate Lung Allograft Survival Is Prolonged by IL-6 Inhibition and ATG Treatment Possibly Through Expansion of Peripheral Regulatory T Cells.

    A. Aoyama, M. Tonsho, R.-N. Smith, R. Colvin, A. Dehnadi, J. Madsen, A. Cosimi, G. Benichou, T. Kawai, J. Allan.

    Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.

    BACKGROUND: Inflammatory responses have been linked to the development of acute and chronic rejection after lung transplantation in various models. Previous studies have demonstrated that…
  • 2016 American Transplant Congress

    Rituximab Induction in Cardiac Transplantation Is Associated with Accelerated Coronary Artery Vasculopathy: CTOT11.

    A. Chandraker, J. Kobashigawa, J. Stehlik, M. Givertz, R. Pierson, S. Pinney, M. Joren, S. Nissen, I. Guleria, Y. Morrison, B. Armstrong, N. Bridges, M. Sayegh, R. Starling.

    On Behalf of the CTOT11 Consortium, Brigham & Women's Hospital, Boston, MA.

    PurposeThe NIH-funded study CTOT11: Prevention of Cardiac Allograft Vasculopathy Using Rituximab (RIT) Therapy in Cardiac Transplantation, was a randomized clinical trial in non-sensitized primary heart…
  • 2016 American Transplant Congress

    Incidence and Renal Consequences of Type 2 Diabetes Mellitus in Kidney Donors.

    H. Ibrahim, A. Matas, D. Berglund, S. Reule, A. Kukla, N. Issa, R. Spong, R. Foley.

    U of MN, Mpls.

    Diabetes Mellitus (DM) continues to be the most common cause of kidney disease. The incidence of DM following kidney donation is unknown. Moreover, whether its…
  • 2016 American Transplant Congress

    Superior Waitlist and Equivalent Transplant Outcomes Among Hepatitis C RNA-Positive Patients Who Are Willing to Accept Hepatitis C Seropositive Kidneys.

    J. Sageshima,1 A. de Mattos,2 C. Troppmann,1 C. Santhanakrishnan,1 J. McVicar,1 B. Gallay,2 M. Gandhi,2 M. Alnimri,2 R. Perez.1

    1Surgery, University of California-Davis, Sacramento, CA; 2Internal Medicine, University of California-Davis, Sacramento, CA.

    Background: kidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is not clear how the acceptance/listing status…
  • 2016 American Transplant Congress

    99% and 100% CPRA Patients Since KAS: A Substantial Increase in Transplants with Strong Evidence of a Bolus Effect.

    A. Kucheryavaya,1 M. Aeder,2 N. Turgeon,3 D. Klassen,1 D. Stewart.1

    1UNOS, Richmond, VA; 2Univ Hosp Case Med Ctr, Cleveland, OH; 3Emory Univ Hosp, Atlanta, GA.

    Background: The Kidney Allocation System (KAS), implemented on 12/4/14, increased allocation priority for candidates with CPRA of 99-100%. Analyses performed on behalf of the OPTN…
  • 2016 American Transplant Congress

    Short Term Changes in HRQOL Following Kidney Transplantation.

    I. Olorundare, H. Ying, M. McAdams-DeMarco, D. Segev.

    JHU, Baltimore.

    Health-Related Quality of Life (HRQOL) is a patient-centered outcome that measures the impact of a disease and its treatment. This is particularly relevant to those…
  • 2016 American Transplant Congress

    Everolimus Plus Reduced-Exposure Cyclosporin versus Mycophenolic Acid Plus Cyclosporin: Seven-Year Follow-Up of Australia and New Zealand Kidney Transplant Recipients in the A2309 Study.

    S. Chadban,1 H. Pilmore,2 G. Russ,3 J. Kanellis,4 S. Campbell,5 P. O'Connell,6 W. Lim,7 M. Lutherborrow,8 N. Kurstjens,8 R. Walker.9

    1Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; 2Auckland Renal Transplant, Auckland City Hospital, Auckland, New Zealand; 3Central Northern Adelaide Ranel and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; 4Renal Medicine, Monash Medical Centre, Melbourne, Australia; 5University of Queensland, Princess Alexandra Hospital, Queensland, Australia; 6Renal Medicine, Westmead Hospital, Sydney, Australia; 7WA Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Australia; 8Novartis Pharmaceuticals, Sydney, Australia; 9Renal Medicine, Alfred Hospital, Melbourne, Australia.

    A2309 was a 2-year, phase III randomized controlled trial evaluating the effect on graft and patient outcomes of three groups:1.5mg everolimus plus low exposure cyclosporine…
  • 2016 American Transplant Congress

    Better Never Than Late: Differences in Outcomes and Risk Factors for Early and Late Rejection After Kidney Transplantation.

    A. Liu, N. Sarabu, A. Joshua.

    Medicine, University Hospitals Case Medical Center, Cleveland, OH.

    Background: Late acute rejection (AR) is associated with inferior outcomes relative to early AR after kidney transplantation. We sought to examine the differences in risk…
  • 2016 American Transplant Congress

    Fc Receptor Binding Assay for Functional Assessment of HLA Antibodies: Initial Clinical Validation.

    E. Woodle, A. Girnita.

    U of Cincinnati, Cincinnati.

    Functional assessment of HLA antibodies (Abs) has historically been limited to complement-based assays, which have known limitations. Moreover, HLA Abs mediate injury by complement-independent mechanisms,…
  • 2016 American Transplant Congress

    Immunogenic HLA-DR Eplet Mismatches as Predictors of Transplant Glomerulopathy.

    D. Blum,1 K. Tinckam,2 M. Marrari,3 J. Kim,2 R. Sapir-Pichhadze.1

    1McGill University, Montreal, Canada; 2University Health Network, Toronto, Canada; 3University of Pittsburgh Medical Center, Pittsburgh.

    BackgroundThe number of HLA-DR eplet mismatches (eplet load) is a risk factor for the development of anti-HLA antibodies and transplant glomerulopathy (TG). In the case…
  • « Previous Page
  • 1
  • …
  • 132
  • 133
  • 134
  • 135
  • 136
  • …
  • 180
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences